# OnCo record nct04980222 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04980222/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04980222", "NCT04980222" ;
  schema:name "A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma"@en ;
  schema:description "A phase 2 trial of Glofitamab, Tocilizumab, Doxorubicin, Vincristine, Prednisone and Rituximab in non-Hodgkin lymphoma, run by Hoffmann-La Roche, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct04980222/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04980222> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2022-03-22" ;
  onco:cancers <https://onco.cc/cancers/non-hodgkin-lymphoma/>, <https://onco.cc/cancers/dlbcl/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/monoclonal-antibody/>, <https://onco.cc/technologies/t-cell-engager/> ;
  onco:drugs <https://onco.cc/drugs/glofitamab/>, <https://onco.cc/drugs/tocilizumab/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/prednisone/>, <https://onco.cc/drugs/rituximab/> ;
  onco:companies <https://onco.cc/companies/flatiron-health/> .